Quarterly ResultMay 7, 2026, 04:04 PM
Annexon: Pivotal Phase 3 GA Data Q4 2026; Q1 Net Loss $44.1M
AI Summary
Annexon, Inc. highlighted significant portfolio progress and reported its first quarter 2026 financial results. The company anticipates topline pivotal Phase 3 data for vonaprument in Geographic Atrophy in Q4 2026 and expects to submit a Biologics License Application for tanruprubart in Guillain-Barré Syndrome in 2026. Annexon reported a net loss of $44.1 million for Q1 2026, but maintained a strong balance sheet with approximately $225 million in cash, cash equivalents, and short-term investments, providing an anticipated runway into the second half of 2027.
Key Highlights
- Topline pivotal Phase 3 data for vonaprument (Geographic Atrophy) expected Q4 2026.
- Tanruprubart EU Marketing Authorization Application for GBS is under review.
- Biologics License Application submission for tanruprubart expected in 2026.
- Proof-of-Concept data for ANX1502 (oral C1 inhibitor) anticipated in 2026.
- Cash, cash equivalents, and short-term investments were $225.0M as of March 31, 2026.
- Anticipated cash runway extends into the second half of 2027.
- Net loss was $44.1M ($0.23 per share) for Q1 2026, compared to $54.4M ($0.37 per share) in Q1 2025.
- R&D expenses decreased to $35.8M in Q1 2026 from $48.2M in Q1 2025.